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Poster Session I S241Introduction: Hematopoietic Stem Cell Transplantation (HSCT)
is a potentially curative modality of therapy for malignant and
non-malignant diseases. As a consequence of the improvement of
supportive measures over recent years (new antibiotics and anti-fun-
gal drugs, increasing experience of HSCT centers, identification of
better donors for unrelated transplants), a increasing number of
long term survivors is at risk for late complications. Secondary ma-
lignancies are described as important causes of late morbidity and
mortality after HSCT. The aim of this study is reporting the inci-
dence and mortality from secondary malignancies over 30 years in
a single center in Brazil.
Patients and Methods: We retrospectively analyzed through our
database 1682 patients submitted to HSCT at the BMT center
from Federal University of Parana from January 1979 to December
2009. We could identify 28 cases of secondary malignancy. Patient
characteristics are summarized in table 1.
Table 1. Patient’s Characteristics
Gender n (%)Male 19
Female 09
Conditioning
Myeloablative 26
Nonmyeloablative 02
Stem cell source
Bone marrow 26
Cord blood 02
HLA match
matched 26
mismatched 02
Diagnosis
Fanconi Anemia 14
Chronic Myeloid Leukemia 6
Myelodisplastic syndrome 2
Severe Aplastic Anemia and PNH 2
Lymphoid malignancies 2
others 2
Graft versus Host Disease
Acute 10 (35)
Chronic 20 (71)Results: Cumulative incidence of secondary malignancy after HSCT
was 2,0%60,5. From 28 cases, 14 had head and neck cancer (tongue)
(50%); 5 post transplant lymphoproliferative disorders related to EBV
(PTLD), three patients had gastrointestinal tract malignancies (esoph-
agus/stomach), three skin cancers (2 basocelular carcinomas and 1ma-
lignant melanoma), and other four cases involving respectively uterus,
lung, CNS and secondary Acute Myeloid Leukemia. With a median
follow-up of 10 years (2-21), overall survival was 72% for patients
with secondary malignancy. However, this curve does not reach a pla-
teau, meaning that those patients are still at risk for death in opposition
to patients without secondary malignancy. Median time from HSCT
to diagnosis was 6.8 years. From 28 patients, 13 (46,5%) died because
of the secondary malignancy. The remaining 15 patients are alive with
no evidence of malignancy in their last follow-up. Prevalence of
chronic graft-versus-host-disease (GVHD) in the secondary
malignancy patient population was 71%.
Conclusion: Secondarymalignancies were important causes of mor-
bidity and mortality after HSCT in our center, similarly to other re-
ports from literature. Incidence was higher among Fanconi anemia
patients with oral chronic graft versus host disease. Identification
of risk factors, prevention, early intervention and close follow up
of this complication are very important measures for long term
survivors of HSCT.237
LONG-TERM SURVIVORSHIP AFTER ALLOGENEIC HEMATOPOETIC CELL
TRANSPLANTATION: STILL ONGOING NON RELAPSE RELATED MORTAL-
ITY & MORBIDITY
Arat, M., Topcuoglu, P., Soydan, E.A., Arslan, €O, €Ozcan, M., Ilhan, O.,
Akan, H., Beksac, M., Konuk, N., Uysal, A.V., Koc, H., Gurman, G.
Ankara University Faculty of Medicine, Ankara, TurkeyAs the number of long-term survivors after allogeneic hematopoi-
etic cell transplantation (allo-HCT) continue to increase, many stud-
ies have been initiated for clinical evaluations and quality-of-life
assessment. We aimed to evaluate disease status, survival probability
and late-transplant-related complications in patients surviving 5 or
more years after allo-HCT in this retrospective single cohort study.
Between 1989 and 2005 total 484 patients underwent allo-HCT
from their HLA-identical relatives. Of 194 long term survivors,
173 (91 M/82 F) were evaluated.
Results:Median age at transplantation was 31 years (range, 14-51).
Their diagnosis was mainly (90%)AML and CML. We used mainly
MAC regimen (90%) and the patients received 52% PBSC. Median
follow-up after allo-HCT was 9.8 years (5.1-20.6 ys). The incidence
of acute and chronic GvHD was 46% and 76.3%, respectively. At
their last control, 36.9% of the patients had still findings related
with chronic GvHD. But only 10 patients (15.6%) were still using
an immunosupresive agent. Twenty-eight patients with chronic
GvHD continued inhaler treatment and was frequently hospitalized
due to non-infectious obliterative pulmonary complications. In pa-
tients with chronic GvHD89% (n5 57) had dry-eye and one patient
underwent cornea transplantation. Cataract was developed in 10 pa-
tients. We observed avascular bone necrosis in 10 patients. Autolo-
gous bone graft was replaced in one of them. Secondary
malignancy was detected in 4 patients. The frequencies of the devel-
opment of dislipidemia, hypertension and type II diabetes mellitus
were 34.7%, 20.8% and 7.5 %, respectively. The social and marital
statuses of the patients were summarized in table 1. Fifteen men
(21.2%) who married at pre- or post-transplant period had become
father to a baby after allo-HCT. The relapse of underlying disease
was detected in 26 patients (only six after 5 years). We performed
a second allo-HCT for relapse (n 5 4) or secondary malignity (n
5 1) using thesame donor. The estimated probabilities of DFS and
OS at 10 and 15 years were 82.1%63.1, 72.3%65.2 and 92.9% 6
2.18, 81.7% 66.1, respectively. In conclusion, mortality due to
transplant-related complications is decreasing in long term survi-
vors. Relapse rate is decreasing dramatically. The rise in cardiovascu-
lar complications is important. Long-term allotransplant
survivorship requires a carefull follow-up both for medical and still
ongoing social problems.
Variables N (%)cGVHD 64/109 (59%)
dry eye 57 (32.9%)
BOS/BOOP 28 (16.2%)
Osteopenia/Osteoporosis 61 (74.4%)
median BMI 25 (12-40)
Obesity (BMI>29) 32 (18.5%)
Low BW (BMI<18.5) 7 (4.02%)
mariage pretx 105 (60.9%)
mariage posttx 26 (15%)
single 39 (22.5%)
fertility 15 (8.6%)
Active working 28.9%
house wife 33.5%
retired 18%
student 2.3%
relapse <5y 20 (11.3%)
relapse >5y 6 (3.4%)238
STABLE PULMONARY FUNCTION OBSERVED OVER TIME IN RECIPIENTS
OF MYELOABLATIVE DOUBLE CORD BLOOD TRANSPLANT: A SINGLE
CENTER EXPERIENCE
Milano, F.1, Riffkin, I.1, Laura, L.1,4, Gutman, J.2, Chien, J.1,4,
Delaney, C.1,3 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Colorado, Denver, CO; 3University ofWashington, Seattle,
WA; 4University of Washington, Seattle, WA
Background: Pulmonary complications, which develop in 40% to
60% of transplant recipients, represent a major cause of morbidity
